Related references
Note: Only part of the references are listed.Class I histone deacetylase inhibitor MS-275 attenuates vasoconstriction and inflammation in angiotensin II-induced hypertension
Yuhee Ryu et al.
PLOS ONE (2019)
Pembrolizumab (P) in patients (pts) with metastatic breast cancer (MBC) with high tumor mutational burden (HTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
Ajjai Shivaram Alva et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Mathematical modeling of tumor-immune cell interactions
Grace E. Mahlbacher et al.
JOURNAL OF THEORETICAL BIOLOGY (2019)
Restriction of PD-1 function by cis-PD-L1/CD80 interactions is required for optimal T cell responses
Daisuke Sugiura et al.
SCIENCE (2019)
In silico simulation of a clinical trial with anti-CTLA-4 and anti-PD-L1 immunotherapies in metastatic breast cancer using a systems pharmacology model
Hanwen Wang et al.
ROYAL SOCIETY OPEN SCIENCE (2019)
Translational Quantitative Systems Pharmacology in Drug Development: from Current Landscape to Good Practices
Jane P. F. Bai et al.
AAPS JOURNAL (2019)
A Computational Model of Neoadjuvant PD-1 Inhibition in Non-Small Cell Lung Cancer
Mohammad Jafarnejad et al.
AAPS JOURNAL (2019)
Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers-Response
Anu Sharma et al.
CLINICAL CANCER RESEARCH (2019)
Prognostic Implications of PD-L1 Expression in Breast Cancer: Systematic Review and Meta-analysis of Immunohistochemistry and Pooled Analysis of Transcriptomic Data
Alexios Matikas et al.
CLINICAL CANCER RESEARCH (2019)
PD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences are Emerging-A Literature Review
Gabrielle Planes-Laine et al.
CANCERS (2019)
Determinants of combination GM-CSF immunotherapy and oncolytic virotherapy success identified through in silico treatment personalization
Tyler Cassidy et al.
PLOS COMPUTATIONAL BIOLOGY (2019)
A mechanistic integrative computational model of macrophage polarization: Implications in human pathophysiology
Chen Zhao et al.
PLOS COMPUTATIONAL BIOLOGY (2019)
Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study
S. Adams et al.
ANNALS OF ONCOLOGY (2019)
Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study
S. Adams et al.
ANNALS OF ONCOLOGY (2019)
Computational Modeling of the Crosstalk Between Macrophage Polarization and Tumor Cell Plasticity in the Tumor Microenvironment
Xuefei Li et al.
FRONTIERS IN ONCOLOGY (2019)
Applications of Quantitative Systems Pharmacology in Model-Informed Drug Discovery: Perspective on Impact and Opportunities
Erica L. Bradshaw et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2019)
MCP-1 is overexpressed in triple-negative breast cancers and drives cancer invasiveness and metastasis
Pranabananda Dutta et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies
Frederick Arce Vargas et al.
CANCER CELL (2018)
Anti-CTLA-4 therapy requires an Fc domain for efficacy
Jessica R. Ingram et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Improving the generation and selection of virtual populations in quantitative systems pharmacology models
Theodore R. Rieger et al.
PROGRESS IN BIOPHYSICS & MOLECULAR BIOLOGY (2018)
Anti-CTLA-4 antibodies in cancer immunotherapy: selective depletion of intratumoral regulatory T cells or checkpoint blockade?
Fei Tang et al.
CELL AND BIOSCIENCE (2018)
Programmed Cell Death Ligand 1 (PD-L1) Signaling Regulates Macrophage Proliferation and Activation
Genevieve P. Hartley et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Population Pharmacokinetic Modeling of a Desmopressin Oral Lyophilisate in Growing Piglets as a Model for the Pediatric Population
Elke Gasthuys et al.
FRONTIERS IN PHARMACOLOGY (2018)
Efficacy and safety of entinostat (ENT) and pembrolizumab (PEMBRO) in patients with melanoma progressing on or after a PD-1/L1 blocking antibody
Sanjiv S. Agarwala et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
Spencer C. Wei et al.
CANCER DISCOVERY (2018)
Tumor mutational burden is a determinant of immune-mediated survival in breast cancer
Alexandra Thomas et al.
ONCOIMMUNOLOGY (2018)
Entinostat Converts Immune-Resistant Breast and Pancreatic Cancers into CheckpointResponsive Tumors by Reprogramming Tumor-Infiltrating MDSCs
Brian J. Christmas et al.
CANCER IMMUNOLOGY RESEARCH (2018)
The clinical promise of immunotherapy in triple-negative breast cancer
Praveen Vikas et al.
CANCER MANAGEMENT AND RESEARCH (2018)
Efficacy/Safety of Entinostat (ENT) and Pembrolizumab (PEMBRO) in NSCLC Patients Previously Treated with Anti-PD-(L) 1 Therapy
M. Hellmann et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Preclinical QSP Modeling in the Pharmaceutical Industry: An IQ Consortium Survey Examining the Current Landscape
Marjoleen J. M. A. Nijsen et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2018)
Breast Cancer Immunotherapy: Facts and Hopes
Leisha A. Emens
CLINICAL CANCER RESEARCH (2018)
New insights into the role of EMT in tumor immune escape
Stephane Terry et al.
MOLECULAR ONCOLOGY (2017)
Tumor Mutational Burden and Response Rate to PD-1 Inhibition
Mark Yarchoan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Myeloid-derived suppressor cells are increased and correlated with type 2 immune responses, malnutrition, inflammation, and poor prognosis in patients with breast cancer
Kenji Gonda et al.
ONCOLOGY LETTERS (2017)
New Combination Strategies Using Programmed Cell Death 1/Programmed Cell Death Ligand 1 Checkpoint Inhibitors as a Backbone
Siwen Hu-Lieskovan et al.
CANCER JOURNAL (2017)
Immunomodulation by Entinostat in Renal Cell Carcinoma Patients Receiving High-Dose Interleukin 2: A Multicenter, Single-Arm, Phase I/II Trial (NCI-CTEP#7870)
Roberto Pili et al.
CLINICAL CANCER RESEARCH (2017)
Entinostat Neutralizes Myeloid-Derived Suppressor Cells and Enhances the Antitumor Effect of PD-1 Inhibition in Murine Models of Lung and Renal Cell Carcinoma
Ashley Orillion et al.
CLINICAL CANCER RESEARCH (2017)
Epigenetic modulation in cancer immunotherapy
Stuart J. Gallagher et al.
CURRENT OPINION IN PHARMACOLOGY (2017)
QSP Toolbox: Computational Implementation of Integrated Workflow Components for Deploying Multi-Scale Mechanistic Models
Yougan Cheng et al.
AAPS JOURNAL (2017)
Model-Based Population Pharmacokinetic Analysis of Nivolumab in Patients With Solid Tumors
G. Bajaj et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2017)
Tumour-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to neoadjuvant chemotherapy of aggressive breast cancer
Y. Asano et al.
BRITISH JOURNAL OF SURGERY (2016)
Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors
Jonathan M. Pitt et al.
IMMUNITY (2016)
Landscape of tumor-infiltrating T cell repertoire of human cancers
Bo Li et al.
NATURE GENETICS (2016)
The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment
Vinit Kumar et al.
TRENDS IN IMMUNOLOGY (2016)
Inhibitors of histone deacetylase 1 reverse the immune evasion phenotype to enhance T-cell mediated lysis of prostate and breast carcinoma cells
Sofia R. Gameiro et al.
ONCOTARGET (2016)
The interplay of epigenetic therapy and immunity in locally recurrent or metastatic estrogen receptor-positive breast cancer: Correlative analysis of ENCORE 301, a randomized, placebo-controlled phase II trial of exemestane with or without entinostat
Yusuke Tomita et al.
ONCOIMMUNOLOGY (2016)
Efficient Generation and Selection of Virtual Populations in Quantitative Systems Pharmacology Models
R. J. Allen et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2016)
Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients
Emanuela Romano et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Model-based clinical pharmacology profiling of ipilimumab in patients with advanced melanoma
Yan Feng et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2014)
Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199
Sylvia Adams et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Combination of HDAC inhibitor MS-275 and IL-2 increased anti-tumor effect in a melanoma model via activated cytotoxic T cells
Yukihiko Kato et al.
JOURNAL OF DERMATOLOGICAL SCIENCE (2014)
Understanding the role of cross-arm binding efficiency in the activity of monoclonal and multispecific therapeutic antibodies
Brian D. Harms et al.
METHODS (2014)
Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells
KiBem Kim et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Antigen affinity, costimulation, and cytokine inputs sum linearly to amplify T cell expansion
Julia M. Marchingo et al.
SCIENCE (2014)
Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression
Limo Chen et al.
NATURE COMMUNICATIONS (2014)
Phenotypic models of T cell activation
Melissa Lever et al.
NATURE REVIEWS IMMUNOLOGY (2014)
Randomized Phase II, Double-Blind, Placebo-Controlled Study of Exemestane With or Without Entinostat in Postmenopausal Women With Locally Recurrent or Metastatic Estrogen Receptor-Positive Breast Cancer Progressing on Treatment With a Nonsteroidal Aromatase Inhibitor
Denise A. Yardley et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
The Histone Deacetylase Inhibitors MS-275 and SAHA Suppress the p38 Mitogen-Activated Protein Kinase Signaling Pathway and Chemotaxis in Rheumatoid Arthritic Synovial Fibroblastic E11 Cells
Qiu-Yi Choo et al.
MOLECULES (2013)
Histone deacetylase inhibitors MS-275 and SAHA induced growth arrest and suppressed lipopolysaccharide-stimulated NF-κB p65 nuclear accumulation in human rheumatoid arthritis synovial fibroblastic E11 cells
Qiu-Yi Choo et al.
RHEUMATOLOGY (2010)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells
Paolo Serafini et al.
CANCER RESEARCH (2008)
A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas
Lia Gore et al.
CLINICAL CANCER RESEARCH (2008)
A methodology for performing global uncertainty and sensitivity analysis in systems biology
Simeone Marino et al.
JOURNAL OF THEORETICAL BIOLOGY (2008)
Optimization of antibody binding to FcγRIIa enhances macrophage phagocytosis of tumor cells
John O. Richards et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies
Shivaani Kummar et al.
CLINICAL CANCER RESEARCH (2007)
CCL2/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers
Bo Huang et al.
CANCER LETTERS (2007)
Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias
Ivana Gojo et al.
BLOOD (2007)
A theoretical framework for quantitative analysis of the molecular basis of costimulation
A Jansson et al.
JOURNAL OF IMMUNOLOGY (2005)
Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma
QC Ryan et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Development of potential antitumor agents. Synthesis and biological evaluation of a new set of sulfonamide derivatives as histone deacetylase inhibitors
G Bouchain et al.
JOURNAL OF MEDICINAL CHEMISTRY (2003)
Share Paper
